BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ARCE Therapeutics\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies ARCE Therapeutics\, Inc.'s drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06680752-3039@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:ARD103: Phase 1/2 readout est. (NCT06680752)
DESCRIPTION:ARD103\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Clinical S
 tudy of ARD103 CAR-T Therapy for Patients With R/R AML or MDS\nEstimated p
 rimary completion: October 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ard103#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06680752
URL:https://assetmemo.bio/drug/ard103#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
